First-in-human safety, tolerability, and pharmacokinetic results of DFV890, an oral low-molecular-weight NLRP3 inhibitor.
Gatlik E, Mehes B, Voltz E, Sommer U, Tritto E, Lestini G, Liu X, Pal P, Velinova M, Denney WS, Fu Y, Opipari A, Dean D, Junge G.
Gatlik E, et al. Among authors: fu y.
Clin Transl Sci. 2024 May;17(5):e13789. doi: 10.1111/cts.13789.
Clin Transl Sci. 2024.
PMID: 38761014
Free PMC article.
Clinical Trial.